24274-48-4

Usage

Uses

Used in Pharmaceutical Research:
1,3-Benzenediol,2-[(1R,6R)-3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-5-propylis used as a potential therapeutic agent for various medical conditions. Its unique molecular structure may allow it to interact with specific biological targets, making it a promising candidate for the development of new drugs.
Used in Chemical Synthesis:
1,3-Benzenediol,2-[(1R,6R)-3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-5-propylcan be used as a starting material or intermediate in the synthesis of other complex organic compounds. Its unique functional groups and structural features may enable the development of novel chemical products with specific applications.
Used in Material Science:
Due to its structural complexity and potential for molecular interactions, 1,3-Benzenediol,2-[(1R,6R)-3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-5-propylmay be utilized in the development of new materials with specific properties, such as improved mechanical strength, thermal stability, or chemical resistance.
Used in Analytical Chemistry:
1,3-Benzenediol,2-[(1R,6R)-3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-5-propylcan be employed as a reference compound or standard in various analytical techniques, such as gas chromatography/mass spectrometry (GC/MS), liquid chromatography/mass spectrometry (LC/MS), or high-performance liquid chromatography (HPLC). This application can be useful for testing methods in clinical toxicology, pharmaceutical research, forensic analysis, and other related fields.

Physiological activity

Cannabidivarin, also known as cannabidivarol or CBDV, is a non-psychoactive cannabinoid found within?Medical Cannabis. It is one of over 100 cannabinoids identified from the Cannabis plant that can modulate the physiological activity of cannabis, or marijuana?3. Compared to its homolog,?Cannabidiol, CBDV is shortened by two methyl (CH2) groups on its side chain. Notably, both?Cannabidiol?and CBDV have demonstrated anticonvulsant activity in animal and human models and are demonstrating promising clinical trial results.

Effects

Cannabidivarol（CBDV） has anticonvulsant effects.

InChI:InChI=1/C19H26O2/c1-5-6-14-10-17(20)19(18(21)11-14)16-9-13(4)7-8-15(16)12(2)3/h9-11,15-16,20-21H,2,5-8H2,1,3-4H3/t15-,16+/m1/s1

Upstream product

• 500-49-2 5-propyl-1,3-benzenediol 
• 156567-57-6 propylzinc bromide 
• 927-77-5 n-propylmagnesium bromide 
• 22972-51-6 (1S,4R)-p-mentha-2,8-dien-1-ol 
• 108-73-6 3,5-dihydroxyphenol 
• 861892-40-2 (4R)-1-methyl-4-(2-(1-propylene))-2-cyclohexene-2-ol 
• 21855-51-6 2,4-dihydroxy-6-propylbenzoic acid ethyl ester 
• 21855-48-1 3,5-dibromo-2,4-dihydroxy-6-propylbenzoic acid ethyl ester 

Downstream Products

• 31262-37-0 tetrahydrocannabivarin 
• 31932-13-5 CBDVA 
• 28172-17-0 (6aS,10aR)-6,6,9-trimethyl-3-propyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-1-ol 
• 31262-38-1 3-norpentyl-3-propyl-Δ⁸-tetrahydrocannabinol 

Relevant academic research and scientific papers

Cannabis. X. The isolation and structures of four new propyl cannabinoid acids, tetrahydrocannabivarinic acid, cannabidivarinic acid, cannabichromevarinic acid and cannabigerovarinic acid, from Thai cannabis, Meao Variant

Four new cannabinoids acids, tetrahydrocannabivarinic acid, cannabidivarinic acid, cannabichromevarinic acid and cannabigerovarinic acid were isolated from Thai Cannabis 'Meao variant' and these structures were elucidated on the basis of chemical and spectral data. This is the first example of the isolation of propyl cannabinoid acid from Cannabis.

A Novel and Practical Continuous Flow Chemical Synthesis of Cannabidiol (CBD) and its CBDV and CBDB Analogues

Cannabidiol is one of the main non-psychoactive cannabinoids present in Cannabis sativa and, in the last decade, it is gaining great interest among the scientific community for its pharmaceutical, nutraceutical, and cosmetic applications. Herein, we report the first continuous flow chemical synthesis of cannabidiol (CBD) and its analogues cannabidivarin (CBDV) and cannabidibutol (CBDB). This approach permits to synthesize products in very good yields (55–59 %), limiting the formation of psychoactive and illegal cannabinoids such as tetrahydrocannabinol (THC).

Design of Negative and Positive Allosteric Modulators of the Cannabinoid CB2Receptor Derived from the Natural Product Cannabidiol

Cannabidiol (CBD), the second most abundant of the active compounds found in the Cannabis sativa plant, is of increasing interest because it is approved for human use and is neither euphorizing nor addictive. Here, we design and synthesize novel compounds taking into account that CBD is both a partial agonist, when it binds to the orthosteric site, and a negative allosteric modulator, when it binds to the allosteric site of the cannabinoid CB2 receptor. Molecular dynamic simulations and site-directed mutagenesis studies have identified the allosteric site near the receptor entrance. This knowledge has permitted to perform structure-guided design of negative and positive allosteric modulators of the CB2 receptor with potential therapeutic utility.

CATALYTIC CANNABINOID PROCESSES AND PRECURSORS

The present disclosure relates to new cannabinoid sulfonate esters and processes for their use to prepare cannabinoids. The disclosure also relates to the use of catalysts and catalytic processes for the preparation of cannabinoids from the cannabinoid sulfonate esters.

METHODS FOR SYNTHESIS OF CANNABINOID COMPOUNDS

The present invention provides simple synthetic routes for the preparation of cannabinoid compounds such as CBD, CBDV, THC, THCV, CBN, HU-308, CBG, CBC, and derivatives thereof, which are stereoselective and provide the desired cannabinoid compound in high yield.

Synthesis of CBD and Its Derivatives Bearing Various C4′-Side Chains with a Late-Stage Diversification Method

A novel synthetic route for making (-)-CBD and its derivatives bearing various C4′-side chains is developed by a late-stage diversification method. Starting from commercially available phloroglucinol, the key intermediate (-)-CBD-2OPiv-OTf is efficiently and regioselectively prepared and further undergoes Negishi cross-coupling to furnish (-)-CBD. This approach allowed an efficient synthesis of (-)-CBD in a five-step total 52% yield on a 10 g scale. Furthermore, diversification on the C4′-side chain with this method can be realized in a wide range.

METHODS OF MANUFACTURING CANNABIDIOL OR CANNABIDIVARIN AND INTERMEDIATES OF MANUFACTURING CANNABIDIOL OR CANNABIDIVARIN

Methods of manufacturing cannabidiol (CBD) and cannabidivarin (CBDV); intermediates of the methods of manufacturing CBD and CBDV; and crystallized CBD and CBDV obtained via described methods.

MIXTURES OF CANNABINOID COMPOUNDS, AND PRODUCTION AND USE THEREOF

Described are specific mixtures comprising one or more (cannabinoid) compounds of the formula (A) and/or one or more of their salts as well was methods for their production. Further described are a compound of the formula (A), a salt of the formula (A) and a corresponding mixture for use as a medicament or, respectively, for use in a method for therapeutic treatment of the human or animal body. Described are also corresponding pharmaceutical formulations, cosmetic preparations and preparations for pleasure and/or nutrition, suitable for consumption, as well as methods for producing CBDV and THCV.

Crystalline cannabidivarin

Solid cannabidivarin, crystalline cannabidivarin, (R,R)-(?)-crystalline cannabidivarin, (S,S)-(+)-crystalline cannabidivarin and substantially pure forms thereof are disclosed herein. Further disclosed are methods of making such cannabidivarin, compositio

Crystalline Form of Cannabidiol

Crystalline Cannabidiol of a novel form, including (R,R)-(?)-crystalline Cannabidiol, as well as methods of making such novel form of Cannabidiol, pharmaceutical formulations comprising such novel form of Cannabidiol, and methods of treating diseases with such novel form of Cannabidiol.